# A Phase II Study of GC101 in NSCLC

Source: https://onco.cc/trials/nct07560111/  
OnCo record `nct07560111` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of GC101 TIL in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Juncell Therapeutics, now recruiting.

## Summary

A Phase II Study of GC101 in NSCLC is a phase 2 interventional study registered as NCT07560111 by Shanghai Juncell Therapeutics, with 28 participants planned, started 2026-06-01 and due to reach its primary completion in 2027-06-01. Interventions recorded: Autologous Tumor Infiltrating Lymphocytes. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07560111
- Phase: 2
- Setting: An Open-Label, Phase II Study to Evaluate the Safety and Efficacy Using Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) in Patients With Non-Small Cell Lung Cancer
- Sponsor: Shanghai Juncell Therapeutics
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT07560111: https://clinicaltrials.gov/study/NCT07560111

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [GC101 TIL](https://onco.cc/drugs/gc101-til/)
- companies: [Shanghai Juncell Therapeutics](https://onco.cc/companies/shanghai-juncell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07560111.json